LARIMAR THERAPEUTICS

Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results

25 мар 2022 06:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

14 фев 2022 15:01:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

22 ноя 2021 06:00:01 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference

15 ноя 2021 06:00:03 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results

12 ноя 2021 06:00:02 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event

16 сен 2021 07:00:02 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

02 сен 2021 15:01:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress

19 авг 2021 06:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

12 авг 2021 06:00:01 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021

08 июл 2021 15:01:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference

11 июн 2021 06:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing

25 май 2021 16:41:45 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces $95 Million Private Placement Financing

21 май 2021 08:18:23 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

20 май 2021 15:31:11 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

11 май 2021 06:00:01 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results

10 май 2021 15:05:01 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

04 мар 2021 06:00:01 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

18 фев 2021 15:01:00 Источник Nasdaq GlobeNewswire